Reduced Central Tolerance in Omenn Syndrome Leads to Immature Self-reactive Oligoclonal T Cells
Overview
Authors
Affiliations
Background: Omenn syndrome (OS) is characterized by a peculiar severe T-cell immune deficiency associated with autoimmunelike manifestations. Dysregulations of the central and peripheral immune tolerance, mediated by the protein autoimmune regulator (AIRE) and regulatory T cells, respectively, were proposed as possible mechanisms of this aberrant inflammatory process.
Objective: We studied mechanisms of central and peripheral tolerance in patients with OS and also examined the gene expression profile associated with OS features.
Methods: T-cell receptor diversity, DNA rearrangement, and the expression of AIRE and forkhead box P3 mRNA as well as the expression of regulatory T cells in cells obtained from patients with OS were studied. Characterization of gene expression in these cells was carried out by using the TaqMan Low-Density Array.
Results: Transcript expression of peripheral blood AIRE but not forkhead box P3 was reduced in patients with OS. The expression of natural killer T and regulatory T cells was normal, although the latter showed an abnormal CD4-negative population. Patients with OS have oligoclonal T cells with limited DNA recombination activity, including the presence of early but not late T-cell maturation events, regardless of the genetic defect underlying the syndrome. The transcriptional profile associated with OS features reveals significant changes in 25.5% of the tested genes compared with normal control.
Conclusion: Our findings suggest that T-cell oligoclonal expansion in OS emanates from an incomplete block before the maturation stage of negative selection, which may explain escape of autoreactive T cells from the thymus. Dysregulated genes in patients with OS are closely involved with self-tolerance and autoimmunity.
Aire Mutations and Autoimmune Diseases.
Wolff A, Oftedal B Adv Exp Med Biol. 2025; 1471:223-246.
PMID: 40067589 DOI: 10.1007/978-3-031-77921-3_8.
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023.
Bastard P, Gervais A, Le Voyer T, Philippot Q, Cobat A, Rosain J Immunol Rev. 2024; 322(1):98-112.
PMID: 38193358 PMC: 10950543. DOI: 10.1111/imr.13304.
Cortesi M, Soresina A, Dotta L, Gorio C, Cattalini M, Lougaris V Front Immunol. 2022; 13:846660.
PMID: 35464467 PMC: 9019165. DOI: 10.3389/fimmu.2022.846660.
Compound heterozygous mutation of Rag1 leading to Omenn syndrome.
Matthews A, Briggs C, Yamanaka K, Small T, Mooster J, Bonilla F PLoS One. 2015; 10(4):e0121489.
PMID: 25849362 PMC: 4388548. DOI: 10.1371/journal.pone.0121489.
Insight into normal thymic activity by assessment of peripheral blood samples.
Machnes-Maayan D, Lev A, Katz U, Mishali D, Vardi A, Simon A Immunol Res. 2014; 61(3):198-205.
PMID: 25294167 DOI: 10.1007/s12026-014-8558-4.